Gilead Sciences (GILD)

$63.33 0.93 (1.49%)

19:59 EST GILD Stock Quote Delayed 30 Minutes

Volume:

Previous Close -

Market Cap 82.35B

PE Ratio 24.08

EPS 2.63

Volume (Avg. Vol.) 9.36M

Day's Range 62.13 - 63.60

52-Week Range 56.56 - 85.97

Dividend & Yield 2.23 (3.52%)

GILD Stock Predictions, Articles, and Gilead Sciences News

From InvestorPlace
From the Web

5 Undervalued Dividend Stocks to Buy

By Thomas Niel Dec 31, 2020

With markets at record highs and interest rates at record lows, consider these five dividend stocks to buy for value and yield.

3 Cheap Stocks Worth Buying Right Now

By Chris Tyler, InvestorPlace Contributor Dec 2, 2020

Cheap stocks can come with many caveats. But sometimes, and as these three companies shares point at, they come equipped with some real value.

Pfizer, Moderna Lead the Vaccine Race: Here’s Where 7 Other Top Vaccine Stocks Stand

By Josh Enomoto, InvestorPlace Contributor Nov 24, 2020

As Pfizer and Moderna take the lead in the novel coronavirus vaccine race, here’s how this affects other Covid-19-related biotech stocks.

4 Top Biotech Stocks to Buy for Operation Warp Speed

By Joel Baglole Nov 3, 2020

The U.S. government has pulled out all the stops to develop a treatment for Covid-19. These biotech stocks are leading the race for a cure.

Which Biotech Stocks Are a Buy on Earnings?

By Louis Navellier, Editor, Growth Investor Nov 3, 2020

If you’re interested in high-growth biotech stocks with superior fundamentals, here are which ones to consider, and which ones to skip.

4 Top Stock Trades for Monday: TWLO, SNAP, SPAQ, GILD

By Bret Kenwell, InvestorPlace Contributor Oct 23, 2020

Twilio, Gilead Sciences, Snap and Spartan Energy Acquisition are our top stock trades to watch on Monday. And here's why.

Gilead Stock: 12 Things for Investors to Know About Remdesivir Approval

By Sarah Smith, InvestorPlace Web Content Producer Oct 23, 2020

Want to know what the big remdesivir approval actually means for Gilead stock? Here's everything investors need to understand.

GILD News: Gilead Stock Pops as FDA Approves Remdesivir Treatment

By Sarah Smith, InvestorPlace Web Content Producer Oct 22, 2020

Gilead stock is climbing higher Thursday after its remdesivir coronavirus treatment received full approval from the FDA. Why it matters.

9 Stocks to Buy for a Wild Ride in November

By Josh Enomoto, InvestorPlace Contributor Oct 15, 2020

With rising coronavirus hospitalizations dominating headlines, investors will shift back toward a pandemic mentality. Here are nine stocks to buy to capitalize on this trend.

7 Highly Rated Pharmaceutical Stocks for Q4

By Joel Baglole Oct 12, 2020

Investors are banking on an upsurge in pharmaceutical stocks once various vaccines and other therapies gain commercial approval from the U.S. Food and Drug Administration (FDA). Here is a list of pharmaceutical companies that stand to benefit in the coming months.